Recently, many studies have investigated the association between orexin A and Alzheimer’s disease (AD). However, it remains to be determined whether the observed changes in orexin A levels are associated with pathological changes underlying AD, or cognitive function. In particular, a direct association between cerebrospinal fluid (CSF) orexin A levels and cognitive function has not been reported to date.
Objective:
The aim of this study was to identify whether there is a direct association between the orexinergic system and cognitive function in AD.
Methods:
For this study, we included 22 patients with AD and 25 control subjects who underwent general physical, neurological, and psychiatric examinations, neuroimaging, and CSF collection by lumbar puncture were enrolled. Correlations between CSF orexin A levels and CSF AD biomarker levels (i.e., levels of phosphorylated tau [p-tau], Aβ42, and Aβ42/Aβ40) were assessed to confirm the results of previous studies. Moreover, the correlation between CSF orexin A levels and Mini-Mental State Examination (MMSE) and Japanese version of the Montreal Cognitive Assessment (MoCA-J) scores were analyzed.
Results:
There was a significant positive correlation between CSF orexin-A levels and cognitive function (MMSE scores: r = 0.591, p = 0.04, MoCA score: r = 0.571, p = 0.006) in AD patients.
Conclusion:
This is the first study to our knowledge demonstrating an association between cognitive function and CSF orexin A levels in AD. Our results suggest the possibility that orexinergic system overexpression is not always a negative factor for cognitive function In AD.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
2.
UrrestarazuE, IriarteJ (2016) Clinical management of sleep disturbances in Alzheimer’s disease: Current and emerging strategies. Nat Sci Sleep8, 21–33.
3.
ShiL, ChenSJ, MaM,
BaoYP,
HanY, WangYM, ShiJ, VitielloMV, LuL (2018) Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev40, 4–16.
4.
HungCM, LiYC, ChenHJ, LuK, LiangCL, LiliangPC, TsaiYD, WangKW (2018) Risk of dementia in patients with primary insomnia: A nationwide population-based case-control study. BMC Psychiatry18, 38.
5.
TononiG, CirelliC (2006) Sleep function and synaptic homeostasis. Sleep Med Rev10, 49–62.
6.
ManderBA, WinerJR, JagustWJ, WalkerMP (2016) Sleep: A novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer’s disease?Trends Neurosci39, 552–566.
OsorioRS, GumbT, PirragliaE, VargaAW, LuSE, LimJ, WohlleberME, DuccaEL, KoushykV, GlodzikL, MosconiL, AyappaI, RapoportDM, de LeonMJ; Alzheimer’s Disease Neuroimaging Initiative (2015) Sleep-disordered breathing advances cognitive decline in the elderly. Neurology84, 1964–1971.
11.
LiguoriC, RomigiA, NuccetelliM, ZanninoS, SancesarioG, MartoranaA, AlbaneseM, MercuriNB, IzziF, BernardiniS, NittiA, SancesarioGM, SicaF, MarcianiMG, PlacidiF (2014) Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol71, 1498–1505.
12.
GabelleA, JaussentI, HirtzC, VialaretJ, NavucetS, GrasselliC, RobertP, LehmannS, DauvilliersY (2017) Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiol Aging53, 59–66.
13.
NishinoS, RipleyB, OvereemS, LammersGJ, MignotE (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet355, 39–40.
14.
RipleyB, OvereemS, FujikiN, NevsimalovaS, UchinoM, YesavageJ, Di MonteD, DohiK, MelbergA, LammersGJ, NishidaY, RoelandseFW, HungsM, MignotE, NishinoS (2001) CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology57, 2253–2258.
15.
HaganJJ, LeslieRA, PatelS, EvansML, WattamTA, HolmesS, BenhamCD, TaylorSG, RoutledgeC, HemmatiP, MuntonRP, AshmeadeTE, ShahAS, HatcherJP, HatcherPD, JonesDN, SmithMI, PiperDC, HunterAJ, PorterRA, UptonN (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A96, 10911–10916.
16.
StanleyEM, FadelJR (2011) Aging-related alterations in orexin/hypocretin modulation of septo-hippocampal amino acid neurotransmission. Neuroscience195, 70–79.
17.
KangJE, LimMM, BatemanRJ, LeeJJ, SmythLP, CirritoJR, FujikiN, NishinoS, HoltzmanDM (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science326, 1005–1007.
18.
RohJH, JiangH, FinnMB, StewartFR, MahanTE, CirritoJR, HedaA, SniderBJ, LiM, YanagisawaM, de LeceaL, HoltzmanDM (2014) Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease. J Exp Med211, 2487–2496.
19.
DauvilliersY (2007) Insomnia in patients with neurodegenerative conditions. Sleep Med8Suppl 4, S27–S34.
20.
WennströmM, LondosE, MinthonL, NielsenHM (2012) Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis29, 125–132.
21.
FronczekR, van GeestS, FrölichM, OvereemS, RoelandseFW, LammersGJ, SwaabDF (2012) Hypocretin (orexin) loss in Alzheimer’s disease. Neurobiol Aging33, 1642–1650.
22.
SlatsD, ClaassenJA, LammersGJ, MelisRJ, VerbeekMM, OvereemS (2012) Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer’s disease and healthy controls. Curr Alzheimer Res9, 1119–1125.
23.
DeuschleM, SchillingC, LewekeF, EnningF, PollmächerT, EsselmannH, WiltfangJ, FrölichL, HeuserI (2014) Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau. Neurosci Lett561, 41–45.
24.
LiguoriC, NuccetelliM, IzziF, SancesarioG, RomigiA, MartoranaA, AmorosoC, BernardiniS, MarcianiMG, MercuriNB, PlacidiF (2016) Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer’s disease. Neurobiol Aging40, 120–126.
25.
OsorioRS, DuccaEL, WohlleberME, TanziEB, GumbT, TwumasiA, TweardyS, LewisC, FischerE, KoushykV, Cuartero-ToledoM, SheikhMO, PirragliaE, ZetterbergH, BlennowK, LuSE, MosconiL, GlodzikL, SchuetzS, VargaAW, AyappaI, RapoportDM, de LeonMJ (2016) Orexin-A is Associated with increases in cerebrospinal fluid phosphorylated-tau in cognitively normal elderly subjects. Sleep39, 1253–1260.
26.
LiguoriC (2017) Orexin and Alzheimer’s disease. Curr Top Behav Neurosci33, 305–322.
27.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
28.
FujiwaraY, SuzukiH, YasunagaM, SugiyamaM, IjuinM, SakumaN, InagakiH, IwasaH, UraC, YatomiN, IshiiK, TokumaruAM, HommaA, NasreddineZ, ShinkaiS (2010) Brief screening tool for mild cognitive impairment in older Japanese: Validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int10, 225–232.
FaganAM, RoeCM, XiongC, MintunMA, MorrisJC, HoltzmanDM (2007) Cerebrospinal fluid tau/beta-amyloid (42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol64, 343–349.
MeccaAP, MichalakHR, McDonaldJW, KempEC, PughEA, BeckerML, MeccaMC, van DyckCH, The Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2018) Sleep disturbance and the risk of cognitive decline or clinical conversion in the ADNI cohort. Dement Geriatr Cogn Disord45, 232–242.
37.
DauvilliersYA, LehmannS, JaussentI, GabelleA (2014) Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy. Front Aging Neurosci6, 119.
38.
ArrigoniE, MochizukiT, ScammellTE (2010) Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol (Oxf)198, 223–235.
39.
JonesBE (2004) Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex. Prog Brain Res145, 157–169.
